Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients with cancer.’
Across melanoma, breast, and renal cancers, the signal is clear: thymic health is a pan‑cancer, tumor agnostic determinant of immunotherapy efficacy.
I think there are huge implications for patient stratification, treatment timing, and immune‑rejuvenating strategies in immunotherapy.”
Title: Thymic health and immunotherapy outcomes in patients with cancer
Authors: Simon Bernatz, Vasco Prudente, Suraj Pai, Asbjørn K. Attermann, Alessandro Di Federico, Andrew Rowan, Selvaraju Veeriah, Lars Dyrskjøt, Leonard Nürnberg, Joao V. Alessi, Patrick A. Ott, Elad Sharon, Allan Hackshaw, Nicholas McGranahan, Christopher Abbosh, Raymond H. Mak, Danielle Bitterman, Mark Awad, Biagio Ricciuti, Charles Swanton, Mariam Jamal-Hanjani, Nicolai J. Birkbak, Hugo J. W. L. Aerts
Read The Full Article
Other articles about Immunotherapy on OncoDaily.
